Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KQB198
- Development stage
- Phase 2
- Lead developer
- Kumquat Biosciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KQB198 is an investigational small molecule immuno-oncology drug developed by Kumquat Biosciences. It is being evaluated in phase 1 clinical trials for the treatment of advanced solid tumors and hematologic malignancies, both as monotherapy and in combination with other anti-cancer agents such as dasatinib or osimertinib. The precise mechanism of action has not been publicly disclosed, but it is classified as an antineoplastic agent within the small molecule class. Clinical studies are focused on determining its safety, tolerability, pharmacokinetics, and preliminary efficacy in adults with relapsed or refractory cancers[2][3][4][6].
Beyond the preview
Go deeper on KQB198.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KQB198.